Sopharma's Profit Down 50% To 9.7 Mln Leva

Sopharma's Profit Down 50% To 9.7 Mln Leva

Sopharma Jsc () ends H1 with net profit in the amount of 9.723 mln leva (4.9 mln euros), which is 49.2% down from the corresponding period in 2007. The factors influencing earnings are changes in revenues figures, operating costs, taxes and net financial costs.

Production sales account for 98.7% of all sales revenues. Those are up 3.4% (by 2.536 mln leva) compared to the same period a year ago.

Sales on the domestic market are dominated by sales of tablet and ampule medicines (86% of all).

Other revenues are up by 228,000 (29%). Sales of materials and goods went up 405,000 leva and sales of services by 343,000 leva.

Costs rose 23%. Costs on external services account for 41% of all and are up by 5.733 mln leva. Advertising accounts for 3.091 mln leva of the total figure. Costs on materials are up by 6.608 mln leva, mainly due to basic materials such as electricity and thermal energy.

Payroll costs, which account for 20% of all, rose by 2.856 mln leva. Amortization (6% of all) is up by 755,000 leva. Other costs (6%) rose by 2.160 mln leva.

Main shareholders are Donev Investmnets Holding Jsc (25.66%), Telso Jsc (23.77%), Telecomplect (20.42%) and Gramercy Emerging Markets Fund (17.24%).

Shares are up 4.85% today to 4.49 leva.

Facebook Коментари

Добави коментар

Екипът на Ви благодари, че използвате кирилица за вашите коментари.
В случай, че коментарът Ви съдържа нецензурни квалификации и лични нападки или обиди на расова, сексуална, етническа или верска основа, той ще бъде изтрит от модератора на сайта.

Абонирайте се за електронния
информационен бюлетин на